Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 15/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783610 | 0.91 | FGFR1 (0.66) | FGFR1HPGDALDH1A1NPC1GLA | |
| SCHEMBL2650466 | 0.90 | FGFR1 (0.65) | FGFR1HPGDALDH1A1NPC1GLA | |
| SCHEMBL2648252 | 0.90 | FGFR1 (0.65) | FGFR1HPGDALDH1A1NPC1GLA | |
| SCHEMBL2648647 | 0.86 | FGFR1 (0.60) | FGFR1HPGDALDH1A1NPC1GLA | |
| SCHEMBL2648736 | 0.86 | FGFR1 (0.60) | FGFR1HPGDALDH1A1NPC1GLA | |
| SCHEMBL2943514 | 0.85 | HPGD (0.58) | FGFR1HPGDALDH1A1NPC1GLA | |
| SCHEMBL2940112 | 0.85 | HPGD (0.60) | FGFR1HPGDALDH1A1NPC1GLA | |
| SCHEMBL2947923 | 0.83 | FGFR1 (0.56) | FGFR1HPGDALDH1A1NPC1GLA | |
| SCHEMBL6752588 | 0.83 | HPGD (0.54) | FGFR1HPGDALDH1A1NPC1GLA | |
| SCHEMBL23680877 | 0.83 | FGFR1 (0.76) | FGFR1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | NEUROSEARCH A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1613618-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087690-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | GABRB2, GABRB1, GABRB3 | FGFR1 3374/4885HPGD 2466/4885ALDH1A1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.